Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022;51(10):875-878.
doi: 10.1159/000521637. Epub 2022 Feb 2.

Safety of Intradialytic Bamlanivimab/Etesevimab Administration in Two COVID-19 Dialysis Outpatients

Lorenzo Gasperoni  1 , Chiara Abenavoli  1 , Gabriele Donati  1 , Anna Scrivo  1 , Fulvia Zappulo  1 , Alessandra Cingolani  1 , Lilio Hu  1 , Gaetano La Manna  1
Affiliations
Case Reports

Safety of Intradialytic Bamlanivimab/Etesevimab Administration in Two COVID-19 Dialysis Outpatients

Lorenzo Gasperoni et al. Blood Purif. 2022.

Abstract

Chronic hemodialysis patients are at high risk of severe COVID-19 disease and death related to the infection. Anti-spike monoclonal antibodies administration reduces risk of disease progression and hospitalization in high-risk subjects but no clear data on end-stage renal disease are available. We report 2 cases of Bamlanivimab/Etesevimab administration to two not hospitalized chronic hemodialysis patients with SARS-CoV2 infection. Since they are large molecules (human immunoglobulin G1) with molecular weight of 146,000 Da, administration was conducted during the second hour of the dialysis session with no adverse reaction. Conclusions: Intradialytic administration of Bamlanivimab/Etesevimab could be considered safe and may allow adequate clinical observation time without hospital-stay prolongation.

Keywords: Bamlanivimab; COVID-19; Etesevimab; Hemodialysis; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

References

    1. Hsu CM, Weiner DE. COVID-19 in dialysis patients: outlasting and outsmarting a pandemic. Kidney Int. 2020;98:1402–4. - PMC - PubMed
    1. Xiong F, Tang H, Liu L, Tu C, Tian J, Lei C, et al. Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China. J Am Soc Nephrol. 2020;31((7)):1387–97. - PMC - PubMed
    1. Hiranoand T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020 May;52((5)):731–3. - PMC - PubMed
    1. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325((7)):632–44. - PMC - PubMed
    1. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid. N Engl J Med. 2021;384:229–37. - PMC - PubMed

Publication types